Equibles does not estimate personal net worth.
Get an email with a short summary when Alx Oncology Holdings Inc publishes a filing, an earnings call transcript or a press release.
Get ALXO alertsBarbara Klencke is recorded as Board Member at Alx Oncology Holdings Inc (ALXO) since January 18, 2025. Barbara Klencke was last confirmed as Board Member at TScan Therapeutics, Inc. (TCRX) in a filing dated April 30, 2024. Alx Oncology Holdings Inc reported in an 8-K filed January 22, 2025 that Barbara Klencke was appointed Class II director, effective January 18, 2025. TScan Therapeutics, Inc. reported in an 8-K filed June 16, 2023 that Barbara Klencke was appointed Audit Committee member, effective June 13, 2023. Barbara Klencke has spoken on 3 earnings calls across 1 company, most recently for Alx Oncology Holdings Inc on May 8, 2026. Alx Oncology Holdings Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alx Oncology Holdings Inc includes Jason Lettmann (CEO and Board Member), Scott Garland (Chairman and Board Member), Harish Shantharam (CFO) and 7 others.
“Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board, for a term expiring at the 2025 annual meeting of stockholders.”
“The Company's Board of Directors appointed Barbara Klencke to the Audit Committee and Gabriela Gruia to the Nominating and Corporate Governance Committee, in each case to replace Ittai Harel, effective as of June 13, 2023.”
“These next few slides describe Avorpisept's mechanism of action. What's so compelling to me is that the mechanism of action is entirely consistent with what we see in the clinical trials.”
“Well, let me start with some quick highlights of the strong results that we have seen with Avorpisep in two HER2-positive breast cancer indications that we have reported on within the past three months.”
“I will start by describing Avorpisept's mechanism of action. CD47 is broadly overexpressed on cancer cells as a means of evading the immune detection, and it does so by sending a don't-eat-me signal.”
2025-01-18–present
Proxy statement
Start not stated–present
Last confirmed April 20, 2026
2023-01-01–2024-04-30
Last confirmed by a filing; no departure on record
Start not stated–2025-09-17
Biotechnology · Healthcare
Board Member
2025-01-18–present
Biotechnology · Healthcare
Board Member
Since 2023-01-01, last confirmed 2024-04-30
